Our knowledge and understanding of the underlying neurobiology and symptomatic expression of ADHD has advanced dramatically over the past decade. Associated with these advances has been a similar explosion of new treatment options to individualize treatment for our patients. This article will: • review strategies to measure ADHD symptoms and functional difficulties while seeking to achieve full symptomatic remission throughout the day • summarize recent findings regarding the management and prioritization of ADHD and comorbid conditions and • discuss the various pharmacologic treatment options with a focus on recently developed molecules and novel delivery systems.
